SUNPHARMA Sun Pharmaceutical Industries Q3 FY25 results (Oct–Dec 2024) and concall
Sun Pharma reported a strong Q3 FY25, driven by robust growth in India and Global Specialty segments, despite a slight decline in the U.S. generics business. Profitability improved with healthy EBITDA margins and a significant increase in adjusted net profit. The company revised its R&D spend guidance for FY25 due to clinical trial delays but remains focused on strategic investments and market share gains.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 13,291 | 13,675 |
| EBITDA | 3,939 | 4,009 |
| Net profit | 3,037 | 2,913 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
